These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27467937)

  • 1. Motolimod effectively drives immune activation in advanced cancer patients.
    Dietsch GN
    Oncoimmunology; 2016 May; 5(5):e1126037. PubMed ID: 27467937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
    Dietsch GN; Randall TD; Gottardo R; Northfelt DW; Ramanathan RK; Cohen PA; Manjarrez KL; Newkirk M; Bryan JK; Hershberg RM
    Clin Cancer Res; 2015 Dec; 21(24):5445-52. PubMed ID: 26152744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
    Chow LQM; Morishima C; Eaton KD; Baik CS; Goulart BH; Anderson LN; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Disis ML; Martins RG
    Clin Cancer Res; 2017 May; 23(10):2442-2450. PubMed ID: 27810904
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Shayan G; Kansy BA; Gibson SP; Srivastava RM; Bryan JK; Bauman JE; Ohr J; Kim S; Duvvuri U; Clump DA; Heron DE; Johnson JT; Hershberg RM; Ferris RL
    Clin Cancer Res; 2018 Jan; 24(1):62-72. PubMed ID: 29061643
    [No Abstract]   [Full Text] [Related]  

  • 7. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
    Ji YG; Shin YM; Jeong JW; Choi HI; Lee SW; Lee JH; Lee KR; Koo TS
    J Pharm Biomed Anal; 2020 Feb; 179():112987. PubMed ID: 31761376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma.
    Zhou Z; Yu X; Zhang J; Tian Z; Zhang C
    Cancer Lett; 2015 Dec; 369(2):298-306. PubMed ID: 26433159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.
    Terunuma H
    J Stem Cells Regen Med; 2012; 8(3):205-6. PubMed ID: 24693200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
    Berger M; Ablasser A; Kim S; Bekeredjian-Ding I; Giese T; Endres S; Hornung V; Hartmann G
    J Immunother; 2009 Apr; 32(3):262-71. PubMed ID: 19242374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human TLR8 Senses RNA From
    Coch C; Hommertgen B; Zillinger T; Daßler-Plenker J; Putschli B; Nastaly M; Kümmerer BM; Scheunemann JF; Schumak B; Specht S; Schlee M; Barchet W; Hoerauf A; Bartok E; Hartmann G
    Front Immunol; 2019; 10():371. PubMed ID: 30972055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
    Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
    J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
    Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
    J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation.
    Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
    Int Immunopharmacol; 2018 Aug; 61():54-63. PubMed ID: 29803914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.